Detail akcie ADMA Biologics online

Business Summary: ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Financial Summary: BRIEF: For the three months ended 31 March 2025, ADMA Biologics Inc revenues increased 40% to $114.8M. Net income increased 51% to $26.9M. Revenues reflect ADMA BioManufacturing segment increase of 42% to $113.7M, United States segment increase of 42% to $110.7M, International segment increase of 5% to $4.1M. Net income benefited from Interest expense decrease of 48% to $2M (expense), Interest income increase of 58% to $608K (income).